Evidence map›Paper›PMID 42321542›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Does

Glen M Blake, Ricardo Donners, Amelia E B Moore, Holly Tovey, Aude Espinasse, Matthew D Blackledge, Sue Chua, Yong Du, Emma Hall, Dow-Mu Koh and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Glen M BlakeDepartment of Biomedical Engineering, School of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK. glen.blake@kcl.ac.uk.ORCID 0000-0002-1530-5267
Ricardo DonnersDepartment of Radiology, University Hospital Basel, Petersgraben 4, Basel, 4031, Switzerland.
Amelia E B MooreDepartment of Cancer Imaging, School of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.
Holly ToveyThe Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK.
Aude EspinasseThe Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK.
Matthew D BlackledgeThe Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK.
Sue ChuaRoyal Marsden Hospital, Downs Road, Sutton, SM2 5PT, UK.
Yong DuRoyal Marsden Hospital, Downs Road, Sutton, SM2 5PT, UK.
Emma HallThe Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK.
Dow-Mu KohThe Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK.
Emilia NuzzaciThe Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK.
Nina TunariuThe Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK.
Christopher C ParkerThe Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK.
Gary J R CookDepartment of Cancer Imaging, School of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe REASURE study investigated imaging biomarkers in men receiving

methodsThirty-four men with prostatic bone metastases received up to six cycles of

resultsADC values increased throughout the study, while SUVmax and Ki decreased. MLR analysis showed that baseline SUVmax and

conclusionsBaseline SUVmax was the best predictor of ADC response, followed by

trial registrationISRCTN ISRCTN17805587. Registered 21/01/15.

Indexed as

Bone NeoplasmsFluorine RadioisotopesPositron Emission Tomography Computed TomographyProstatic NeoplasmsRadiumSodium FluorideAgedHumansMaleMiddle AgedTreatment OutcomeFluorine-18Fluorine RadioisotopesRadiumRadium-223Sodium Fluoride18F]NaF PET/CT imagingBone metabolic flux (Ki)Bone metastasesDiffusion-weighted MRIMaximum standardised uptake valuesProstate cancerRadium-223 therapy

Identifiers

PMID42321542
PMCPMC13526093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.